Genpharmasec Complete Financial Statements
In FY2026, Genpharmasec (GENPHARMA) reported revenue ₹57 Cr, net profit ₹1 Cr and EPS ₹0.02, with a net profit margin of 1.8% and ROE of 1.5%. Full financial statements from FY2023 to FY2026 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Genpharmasec share price chart.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
GENPHARMA Revenue, Net Profit & EBITDA — Year-on-Year Growth
GENPHARMA YoY (Mar 2025 vs Mar 2026) — revenue +280.0%, expenses +253.3%. Analyse GENPHARMA institutional holdings to track promoter, FII and institutional holdings.
GENPHARMA Income Statement — Revenue, EBITDA & Net Profit
Genpharmasec revenue ₹57 Cr, EBITDA ₹3 Cr, net profit ₹1 Cr, EPS ₹0.02 (2026) — net profit margin 1.8%. Examine GENPHARMA quarterly trends for recent quarterly revenue, profit and EPS trends.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57 | 33 | 15 | 13 | 41 | 7 | 11 | 6 | 9 | 8 | 6 | 6 | 7 |
| Expenses | 53 | 33 | 15 | 11 | 41 | 6 | 10 | 5 | 8 | 8 | 6 | 6 | 6 |
| EBITDA | 3 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Operating Profit Margin % | 4.00% | -1.00% | -7.00% | 8.00% | -3.00% | 2.00% | 0.00% | 4.00% | 8.00% | -1.00% | 3.00% | 0.00% | 0.00% |
| Depreciation | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | -1 | 0 | 1 | -1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 1 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 |
| Net Profit | 1 | -1 | 0 | 1 | -1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Earnings Per Share (₹) | 0.02 | -0.02 | -0.01 | 0.02 | -0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.04 | 0.00 | 0.00 |
GENPHARMA Balance Sheet — Assets, Liabilities & Shareholders' Equity
GENPHARMA total assets ₹138 Cr, total equity ₹66 Cr, total liabilities ₹ Cr (2026) — ROE 1.5%.
| Particulars | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| Total Assets | 138 | 80 | 71 | 20 |
| Current Assets | 81 | 27 | 41 | 19 |
| Fixed Assets | 23 | 8 | 1 | 0 |
| Capital Work in Progress | 0 | 0 | 0 | 0 |
| Investments | 14 | 19 | 19 | 1 |
| Other Assets | 0 | 54 | 51 | 19 |
| LIABILITIES | ||||
| Total Liabilities | ||||
| Current Liabilities | 26 | 5 | 4 | 3 |
| Non-Current Liabilities | ||||
| SHAREHOLDERS' EQUITY | ||||
| Total Equity | 66 | 65 | 65 | 15 |
| Share Capital | 55 | 55 | 55 | 28 |
| Reserves & Surplus | 11 | 10 | 9 | -12 |
GENPHARMA Cash Flow Statement — Operating, Investing & Financing
Genpharmasec operating cash flow ₹3 Cr, investing ₹-15 Cr, financing ₹-1 Cr, net cash flow ₹-14 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 |
|---|---|---|---|
| Operating Activities | 3 | -3 | -3 |
| Investing Activities | -15 | -28 | 0 |
| Financing Activities | -1 | 48 | 3 |
| Net Cash Flow | -14 | 17 | 0 |